Eliquis (EL-a-kwis) will be the next ORAL anticoagulant

Eliquis (EL-a-kwis) will be the next ORAL anticoagulant to compete with Pradax and Xarelto.

It's initially approved to prevent thrombosis after hip or knee replacement surgery. But it's likely to be approved later this year to prevent strokes due to atrial fibrillation.

Eliquis (apixaban) and Xarelto (rivaroxaban) are direct factor Xa inhibitors. Pradax (dabigatran) is a direct thrombin inhibitor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote